首页> 外文期刊>Bone >Transcriptomic and bioinformatic analysis of Clcn7-dependent Autosomal Dominant Osteopetrosis type 2. Preclinical and clinical implications
【24h】

Transcriptomic and bioinformatic analysis of Clcn7-dependent Autosomal Dominant Osteopetrosis type 2. Preclinical and clinical implications

机译:CLCN7依赖性常染色体显性骨质术症型转录组和生物信息分析2.临床前和临床意义

获取原文
获取原文并翻译 | 示例
           

摘要

Autosomal Dominant Osteopetrosis type 2 (ADO2) is a rare genetic disease characterized by dense yet fragile bones. To date, the radiological approach remains the gold standard for ADO2 diagnosis. However, recent observations unveiled that ADO2 is a systemic disease affecting various organs beyond bone, including lung, kidney, muscle, and brain. Monitoring disease status and progression would greatly benefit from specific biomarkers shared by the affected organs. In this work, data derived from RNA deep sequencing (RNA dSeq) of bone, lung, kidney, muscle, brain, and osteoclasts isolated from wildtype (WT) and Clcn7(G213R) ADO2 mice were subjected to gene ontology and pathway analyses. Results showed the presence of alterations in gene ontology terms and pathways associated with bone metabolism and osteoclast biology, including JAK-STAT, cytokine-cytokine receptor, and hematopoietic cell lineage. Furthermore, in line with the multiorgan alterations caused by ADO2, the analysis of soft organs showed an enrichment of PPAR and neuroactive ligand-receptor interaction pathways known to be involved in the onset of tissue fibrosis and behavioral alterations, respectively. Finally, we observed the modulations of potential ADO2 biomarkers in organs and cells of ADO2 mice and in the peripheral blood mononuclear cells of patients, using conventional methods. Of note, some of these biomarkers could be possibly responsive to an effective experimental therapy based on a mutation-specific siRNA. Overall, the identified gene signature and the soluble forms of the encoded proteins could potentially represent reliable disease biomarkers that could improve the ADO2 diagnosis, the monitoring of both the skeletal and non-skeletal dysfunctions, and the assessment of the response to therapy.
机译:常染色体显性骨质棘症2型(ADO2)是一种稀有遗传症,其特征在于致密又脆弱的骨骼。迄今为止,放射线方法仍然是ADO2诊断的金标准。然而,最近的观察结果揭开了ADO2是一种影响超出骨骼的各种器官的全身疾病,包括肺,肾,肌肉和脑。监测疾病状况和进展将极大地受到受影响机构共享的特定生物标志物。在这项工作中,对骨,肺,肾脏,肌肉,脑和从野生型(WT)和CLCN7(G213R)和CLCN7(G213R)ADO2小鼠分离的RNA深度测序(RNA DSEQ)衍生的数据进行基因本体和途径分析。结果表明,与骨代谢和骨质体生物学相关的基因本体论术语和途径的发生,包括jak-stat,细胞因子 - 细胞因子受体和造血细胞谱系。此外,根据ADO2引起的多功能变化,软器官的分析表明,富集的PPAR和神经活性配体 - 受体相互作用途径分别涉及组织纤维化和行为改变的发作。最后,我们使用常规方法观察了在ADO2小鼠的器官和患者的外周血单核细胞中的潜在ADO2生物标志物的调节。值得注意的是,这些生物标志物中的一些可能对基于突变特异性siRNA的有效实验疗法敏感。总体而言,所鉴定的基因签名和可溶性形式的编码蛋白质可能是可能代表可靠的疾病生物标志物,可以改善ADO2诊断,监测骨骼和非骨骼功能障碍的监测,以及对治疗的反应的评估。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号